These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6397176)

  • 21. Safe use of ocular drugs in the elderly.
    Fraunfelder FT; Meyer SM
    Geriatrics; 1984 Apr; 39(4):97-102. PubMed ID: 6706121
    [No Abstract]   [Full Text] [Related]  

  • 22. Ocular Side Effects of Common Systemic Medications and Systemic Side Effects of Ocular Medications.
    Syed MF; Rehmani A; Yang M
    Med Clin North Am; 2021 May; 105(3):425-444. PubMed ID: 33926639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic effects of topical ophthalmic medications.
    Selvin BL
    South Med J; 1983 Mar; 76(3):349-58. PubMed ID: 6131541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timolol gel versus acetazolamide in the prophylaxis of ocular hypertension after phacoemulsification.
    Kanellopoulos AJ; Perry HD; Donnenfeld ED
    J Cataract Refract Surg; 1997 Sep; 23(7):1070-4. PubMed ID: 9379379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed topical combinations in glaucomatous patients and ocular discomfort.
    Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
    Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic side effects associated with the ophthalmic administration of timolol.
    Munroe WP; Rindone JP; Kershner RM
    Drug Intell Clin Pharm; 1985 Feb; 19(2):85-9. PubMed ID: 3882377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Systemic side effects of topical ophthalmic drugs].
    Bodd E; Lunde PK
    Tidsskr Nor Laegeforen; 1990 Apr; 110(11):1375. PubMed ID: 2339383
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
    Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group.
    Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
    Ophthalmology; 1998 Oct; 105(10):1952-9. PubMed ID: 9787369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
    Lass JH; Khosrof SA; Laurence JK; Horwitz B; Ghosh K; Adamsons I
    Arch Ophthalmol; 1998 Aug; 116(8):1003-10. PubMed ID: 9715679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypotony and choroidal detachment as a complication of topical combined timolol and dorzolamide.
    Sharma T; Salmon JF
    J Ocul Pharmacol Ther; 2007 Apr; 23(2):202-5. PubMed ID: 17444809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical carbonic anhydrase inhibitors.
    Talluto DM; Wyse TB; Krupin T
    Curr Opin Ophthalmol; 1997 Apr; 8(2):2-6. PubMed ID: 10168353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group.
    Strohmaier K; Snyder E; DuBiner H; Adamsons I
    Ophthalmology; 1998 Oct; 105(10):1936-44. PubMed ID: 9787367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chloramphenicol in ophthalmic instillation and risk of generalized sensitization].
    Verin P; Sekkat A; Morax S
    Bull Soc Ophtalmol Fr; 1972 Mar; 72(3):365-70. PubMed ID: 4643424
    [No Abstract]   [Full Text] [Related]  

  • 36. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol.
    Stewart WC; Halper LK; Johnson-Pratt L; Polis A; Hartenbaum D
    J Ocul Pharmacol Ther; 2002 Jun; 18(3):211-20. PubMed ID: 12099542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine.
    Fraunfelder FT; Meyer SM
    Am J Ophthalmol; 1985 Mar; 99(3):362-3. PubMed ID: 3976814
    [No Abstract]   [Full Text] [Related]  

  • 38. Skin reactions due to eye drops: report of two cases.
    Lazarov A; Amichai B
    Cutis; 1996 Nov; 58(5):363-4. PubMed ID: 8934079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor.
    Pfeiffer N
    Surv Ophthalmol; 1997; 42(2):137-51. PubMed ID: 9381367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.